Financial Accountant

Req ID:  103520

Edinburgh, GB, EH14 4AP

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Job Summary

An opportunity has arisen to apply for the role of Financial Accountant, within the European Accounting and Shared Services Team. This role has been created as a new role within the team and may suit a part qualified accountant looking to complete their training. The successful applicant will work closely with their manager on the accounting, reporting and compliance for allocated businesses. You will support the existing finance team in implementing good accounting practices to ensure the on time and accurate submission of results each month.


The key to this role is the ability to support your manager on the delivery of accurate results on a tight monthly closing schedule whilst building a relationship with the on-site business finance team(s) to improve forecast accuracy.


The following are minimum requirements related to the position:

  • A minimum of Part Qualified accountant
  • Previous experience in a complex, rapidly growing organization
  • Some knowledge / experience of US GAAP
  • Experience within a multi-location / country environment
  • An understanding of internal control processes, previous exposure to SoX would be advantageous
  • Excellent communication skills
  • Fluency in written and spoken English
  • Awareness of large ERP systems


Salary for this position is competitive and dependent upon qualifications and/or relevant experience. 

The closing date for applications is 16 April 2021.

About Corporate Functions
The Corporate Functions provide operational support across Charles River in areas such as Human Resources, Finance, IT, Legal, Sales, Quality Assurance, Marketing, and Corporate Development. They partner with their colleagues across the company to develop and drive strategies and to set global standards. The functions are essential to providing a bridge between strategic vision and operational readiness, to ensure ongoing functional innovation and capability improvement. 


About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.


With over 17,000 employees within 90 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2019, revenue increased to $2.62 billion. 


At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2019.